Dr. Reddy’s Laboratories has purchased worldwide exclusive intellectual property rights for Fondaparinux sodium, its generic anti-coagulant drug, from its Australian partner, Alchemia Limited, for $17.5 million. Fondaparinux is a generic version of the anticoagulant drug Arixtra, which is approved in the U.S. and Europe for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and is also indicated for the prevention of DVT after major surgery, such as knee and hip rep...